For STAT, Ed Silverman reports on growing concerns about the industry ties of the new nominee for FDA commissioner. “The nomination comes at a pivotal time for the FDA,” he writes. “The agency is under increasing pressure from drug companies and patients to approve more medicines faster than ever. Congress is considering legislation designed to accelerate innovation, although some critics say the effort threatens to lower safety standards for approving some products.”
© 2023 Mad in America Foundation